Wuhan Createrna Science and Technology Co., Ltd
Quick facts
Phase 3 pipeline
- Eculizumab Injection · Immunology
Eculizumab is a monoclonal antibody that inhibits the complement protein C5, blocking the formation of the membrane attack complex and reducing complement-mediated cell destruction. - MY008211A tablets
MY008211A tablets' mechanism is unknown.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Wuhan Createrna Science and Technology Co., Ltd portfolio CI brief
- Wuhan Createrna Science and Technology Co., Ltd pipeline updates RSS
Frequently asked questions about Wuhan Createrna Science and Technology Co., Ltd
What is Wuhan Createrna Science and Technology Co., Ltd's pipeline?
Wuhan Createrna Science and Technology Co., Ltd has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Eculizumab Injection, MY008211A tablets.
Related
- Sector hub: All tracked pharma companies